Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate (68Ga-DOTATATE) PET standardised uptake value (SUV) has shown conflicting results in the prediction of tumour response to radionuclide therapy.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,
Keywords: 68Ga-DOTATATE PET-CT, SUV parameters, Tumor response, Somatostatin receptor tumor volume,
Introduction: Increased tumour lesion absorbed dosimetry (TLAD) from peptide receptor radionuclide therapy (PRRT) is associated with neuroendocrine tumours (NET) response. Responses to PRRT might be impacted by NET grade, site of origin and use of concurrent chemotherapy.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,
Keywords: 68Ga-DOTATATE PET, Tumor Dosimetry, Response,
Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate Positron Emission Tomography (68Ga-DOTATATE PET) standardised uptake value (SUV) has shown conflicting results in the prediction of tumour lesion absorbed dosimetry (TLAD).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burg M,
Keywords: 68Ga-DOTATATE PET-CT, Tumor Dosimetry, SUV predictors,
Introduction: Bulky disease from NET is an adverse prognostic factor for response to 177Lu-DOTA-octreotate (LuTate) PRCRT. 90Y-DOTA-octreotate (YTate) has more penetrating particulate emissions.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Kong G, Callahan J, Hofman M, Pattison D, Akhurst T,